GeneOne Life Science Inc (011000) — Working Capital to Net Assets Ratio
GeneOne Life Science Inc (011000) has a Working Capital to Net Assets ratio of -84.0% as of December 2025. Working capital of ₩-34.37 Billion (current assets of ₩19.44 Billion minus current liabilities of ₩53.81 Billion) is measured against net assets of ₩40.90 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See how leveraged is GeneOne Life Science Inc's balance sheet to measure how much of total assets are equity-financed.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
GeneOne Life Science Inc Working Capital to Net Assets (2013–2025)
This chart shows how GeneOne Life Science Inc's Working Capital to Net Assets ratio has evolved across 13 annual periods from 2013 to 2025. As of December 2025, the ratio stands at -84.0%, reflecting working capital of ₩-34.37 Billion against net assets of ₩40.90 Billion KRW. Check how tangible is GeneOne Life Science Inc's equity to evaluate the tangible quality of the company's equity base.
Annual Working Capital to Net Assets for GeneOne Life Science Inc (2013–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for GeneOne Life Science Inc from 2013 to 2025, covering 13 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see GeneOne Life Science Inc (011000) total market value.
| Year | WC/NA Ratio | Working Capital (KRW) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -84.0% | ₩-34.37 Billion | ₩40.90 Billion | ₩19.44 Billion | ₩53.81 Billion | ▼ -67.8 pp |
| 2024 | -16.2% | ₩-13.87 Billion | ₩85.61 Billion | ₩28.64 Billion | ₩42.51 Billion | ▼ -26.7 pp |
| 2023 | 10.5% | ₩11.71 Billion | ₩111.49 Billion | ₩34.57 Billion | ₩22.87 Billion | ▼ -11.1 pp |
| 2022 | 21.6% | ₩39.23 Billion | ₩181.47 Billion | ₩73.06 Billion | ₩33.84 Billion | ▼ -27.0 pp |
| 2021 | 48.6% | ₩99.87 Billion | ₩205.45 Billion | ₩134.63 Billion | ₩34.76 Billion | ▼ -24.5 pp |
| 2020 | 73.1% | ₩72.06 Billion | ₩98.51 Billion | ₩108.76 Billion | ₩36.71 Billion | ▲ +15.2 pp |
| 2019 | 58.0% | ₩13.94 Billion | ₩24.06 Billion | ₩36.60 Billion | ₩22.65 Billion | ▼ -7.9 pp |
| 2018 | 65.9% | ₩19.37 Billion | ₩29.41 Billion | ₩38.18 Billion | ₩18.81 Billion | ▼ -5.5 pp |
| 2017 | 71.4% | ₩26.08 Billion | ₩36.54 Billion | ₩34.65 Billion | ₩8.57 Billion | ▲ +3.8 pp |
| 2016 | 67.6% | ₩24.23 Billion | ₩35.85 Billion | ₩52.91 Billion | ₩28.68 Billion | ▼ -4.9 pp |
| 2015 | 72.5% | ₩28.59 Billion | ₩39.44 Billion | ₩35.28 Billion | ₩6.69 Billion | ▲ +0.0 pp |
| 2014 | 72.5% | ₩25.16 Billion | ₩34.73 Billion | ₩29.44 Billion | ₩4.28 Billion | ▲ +17.2 pp |
| 2013 | 55.2% | ₩13.09 Billion | ₩23.71 Billion | ₩19.50 Billion | ₩6.41 Billion | — |